Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: anakinra treatment + juvenile arthritis + arthritis  Related to the article below (Last Update: 5/12/2008)

Career Success With A Chronic Illness
North American Press Syndicate, NY - May 1, 2008
HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of ...
Abbott Announces HUMIRA? (adalimumab) Approved In Japan For The ...
Medical News Today (press release), UK - Apr 21, 2008
HUMIRA is also approved for the treatment of juvenile idiopathic arthritis (JIA) in the United States, and review for JIA in Europe is ongoing. ...ABT
FDA Approval: Orencia
Medscape (subscription) - Apr 17, 2008
Describe the appropriate use of abatacept for the treatment of juvenile idiopathic arthritis. Identify adverse events related to the use of abatacept for ...
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the ...
CNNMoney.com (press release) - Apr 16, 2008
HUMIRA is also approved for the treatment of juvenile idiopathic arthritis (JIA) in the United States, and review for JIA in Europe is ongoing. ...ABT
Source: Google News

[CITATION] Treatment of systemic onset juvenile rheumatoid arthritis with anakinra
PI Irigoyen, J Olson, C Hom, NT Ilowite - Arthritis Rheum, 2004

… 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. -
JW Verbsky, AJ White - J Rheumatol, 2004 - ncbi.nlm.nih.gov
... Systemic onset juvenile rheumatoid arthritis (SOJRA) is a ... therapies show promise
in the treatment of chronic ... interleukin 1 receptor antagonist anakinra in 2 ...

Medical Treatment of Juvenile Idiopathic Arthritis -
PJ Hashkes, RM Laxer - JAMA, 2005 - Am Med Assoc
... 150. Initial promising results using anakinra for systemic ... 4. Algorithm for Medical
Treatment of Oligoarthritis in Juvenile Idiopathic Arthritis ...

Targeting interleukin-1 in the treatment of rheumatoid arthritis -
JM Dayer, B Bresnihan - Arthritis & Rheumatism, 2002 - doi.wiley.com
... 1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. ...
Treatment of rheumatoid arthritis with anakinra, a recom- binant ...

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage -
SB Abramson, A Amin - Rheumatology, 2002 - Br Soc Rheumatology
... with functional and work disability [2]. Anakinra also provided ... in a new era in the
treatment of RA. ... urine of children with systemic juvenile chronic arthritis ...

… patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment … -
LBA van de Putte, C Atkins, M Malaise, J Sany, AS … - British Medical Journal, 2004 - ard.bmj.com
... Effects of treatment with a fully human anti-tumour necrosis factor monoclonal ... Arthritis
Rheum 2002;46 (uppl 9):S171. ... Kineret TM (anakinra) [package insert]. ...

… statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic … -
DE Furst, FC Breedveld, JR Kalden, JS Smolen, CE … - British Medical Journal, 2002 - ard.bmj.com
... Etanercept in children with polyarticular juvenile rheumatoid arthritis. ... Treatment
of rheumatoid arthritis with Anakinra, a recombinant human ...

Infectious complications of biologic treatments of rheumatoid arthritis. -
AK Mohan, TR Cot?, JN Siegel, MM Braun - Current Opinion in Rheumatology, 2003 - co-rheumatology.com
... Crohn disease; RA, rheumatoid arthritis; JRA, juvenile rheumatoid arthritis ... a
recombinant IL-1 receptor antagonist, anakinra for the treatment of moderately ...

New Drugs for Rheumatoid Arthritis -
NJ Olsen, CM Stein - The New England Journal of Medicine, 2004 - nejm.org
... Concomitant use of anakinra and a TNF antagonist may ... finding a place in the treatment
of many ... 113 ankylosing spondylitis, 114 juvenile arthritis, 113 Still's ...
-

The use of anakinra in juvenile arthritis -
A Reiff - Current Rheumatology Reports, 2005 - Springer
... 83. Irigoyen PI, Olson J, Hom C, et al.: Treatment of systemic onset juvenile
rheumatoid arthritis with anakinra. Arthritis Rheum 2004; 50 (Suppl): S437. ...

Source: Google Scholar
 
 

Anakinra in the treatment of children with juvenile arthritis

 
 
Researchers from the Baylor Institute for Immunology Research in Dallas report on the successful treatment of children with systemic onset juvenile idiopathic arthritis ( SoJIA ) in whom previous therapies have failed.

The study has been published in The Journal of Experimental Medicine.

Approximately 250,000 children in the U.S. suffer from juvenile arthritis. SoJIA accounts for about 10 percent of all juvenile arthritis cases with unknown causes.
Early symptoms, which often go undiagnosed, may include fever and a rash.
As the disease progresses, anemia and other blood-related issues develop, as do inflammation and joint pain.
Depending on the duration and severity of the disease long-term disabilities may develop.

" Most of the children in our study have suffered from persistent fever and arthritis for years. Additionally, they have suffered from side effects resulting from conventional medications. Through this research, we found that we could not only control the disease, but also allow these children to grow and carry out normal lives," said Virginia Pascual, from the Baylor Institute for Immunology Research ( BIIR ).

In collaboration with researchers from Texas Scottish Rite Hospital for Children in Dallas, the BIIR team identified children with this form of juvenile arthritis who had not responded to other treatment regimens.

They discovered that white blood cells from these SoJIA patients expressed higher levels of certain immune system genes than white blood cells from healthy individuals.
They also found that blood serum from the SoJIA patients caused healthy white blood cells to start overexpressing these genes and to secrete higher levels of interleukin-1b.
Interleukins are proteins made by white blood cells that help regulate the immune system.
The researchers observed that higher IL-1b secretion also occurred in SoJIA patients.

“ We felt that oversecretion of IL-1b might play a significant role in SoJIA and that inhibiting IL-1b activity could be beneficial, ” said Dr. Banchereau, director, BIIR.

To test this hypothesis, nine SoJIA patients received a drug, called Anakinra, which inactivated IL-1.

Anakinra ( Kineret ) is a genetically engineered version of the IL-1 receptor that has been used to treat rheumatoid arthritis.

All nine patients responded to the therapy.
Seven patients had systemic symptoms, such as fever.
A week after the first treatment the fever was gone from all seven and did not return for the length of the one-year follow up.
Eight of the nine had active arthritis. In these patients, the researchers observed decreases in the arthritic symptoms in the joints as well as improvement of hemoglobin levels, white blood cell count and a number of other indicators of arthritis. They found that the therapy completely restored the function of six of the eight patients and lessened the symptoms of the remaining two.

Source: Baylor Research Institute ( BIR ), 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page